Neurobiology of lithium: An update

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 6, 1998, Pages 37-47

  Lenox, Robert H ^a   McNamara, Robert K ^a   Papke, Roger L ^a   Manji, Husseini K ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENYLATE CYCLASE; AMINO ACID; AMPHETAMINE; CALCIUM ION; DOPAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; INOSITOL PHOSPHATE; LITHIUM; MARCKS PROTEIN; NALOXONE; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; SEROTONIN; TAMOXIFEN CITRATE;

CALCIUM CELL LEVEL; DEPRESSION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; MAJOR DEPRESSION; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MEMBRANE TRANSPORT; NEUROANATOMY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; SECOND MESSENGER;

BIPOLAR DISORDER; BRAIN; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; GENE EXPRESSION; GENES, FOS; GENES, IMMEDIATE-EARLY; GTP-BINDING PROTEINS; HUMANS; LITHIUM; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; SIGNAL TRANSDUCTION;

EID: 0031838509     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (178)

1. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London, England: Walton and Maberly; 1859
2. Trousseau A. Clinique Medicale de l'Hotel-Dieu de Paris. 3rd ed. Paris, France: J-B Balliere et Fils; 1868
3. Ure A. Researches on gout. Medical Times 1844/1845;11:145
4. Aulde J. The use of lithium bromide in combination with solution of potassium citrate. Medical Bulletin (Philadelphia) 1887;9:35-39, 69-72, 228-233
5. Lange C. Om Periodiske Depressionstilstande og deres Patogenese. Copenhagen, Denmark: Jacob Lunds Forlag; 1886
6. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;36:349-352
7. Schou M. Lithium research at the Psychopharmacology Research Unit, Risskov, Denmark: a historical account. In: Schou M, Stromgren E, eds. Origin, Prevention and Treatment of Affective Disorders. London, England: Academic Press; 1979:1-8
8. Lenox RH. Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. In: Erlich YH, ed. Molecular Mechanisms of Neuronal Responsiveness. Adv Exp Biol Med, vol 221. New York, NY: Plenum Press 1987;515-530
9. Lenox RH, Manji HK. Lithium. In: Nemeroff C, Schatzberg, eds. American Psychiatric Association Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995;303-349
10. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-543
11. Manji HK, McNamara RK, Lenox RH. Mechanisms of action of lithium in bipolar illness. In: Montgomery S, Halbreich U, eds. Pharmacology of Mood and Cognition. Washington, DC: American Psychiatric Press. In press
12. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
13. Baldessarini RJ, Tondo L, Faedda GL, et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-448
14. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448-455
15. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
16. Hitzemann R, Mark C, Hirschowitz J, et al. RBC lithium transport in the psychoses. Biol Psychiatry 1989;25:296-304
17. Sarkadi B, Alifimoff JK, Gunn RB, et al. Kinetics and stoichiometry of Nadependent Li transport in human red blood cells. J Gen Physiol 1978;72: 249-265
18. El-Mallakh RS. Lithium Actions and Mechanisms. Washington, DC: American Psychiatric Press; 1996
19. Dubovsky SL. Calcium channel antagonists as novel agents for manic-depressive disorder. In: Nemeroff C, Schatzberg A, eds. American Psychiatric Association Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995;377-390
20. Arystarkhoua E, Sweadner KJ. Isoform-specific monoclonal antibodies to Na,K-ATPase α subunits: evidence for a tissue-specific post-translational modification of the α subunit. J Biol Chem 1996;271:23407-23417
21. Grillo C, Piroli G, Gonzalez SL, et al. Glucocorticoid regulation of mRNA encoding (Na+K) ATPase α 3 and β 1 subunits in rat brain measured by in situ hybridization. Brain Res 1994;657:83-91
22. Lecuona E, Luquin S, Avila J, et al. Expression of the β 1 and β 2 (AMOG) subunits of the Na,K-ATPase in neural tissues: cellular and developmental distribution patterns. Brain Res Bull 1996;40:167-174
23. Malik N, Canfield VA, Beckers MC, et al. Identification of the mammalian Na,K-ATPase subunit. J Biol Chem 1996;271:22754-22758
24. Munzer JS, Daly SE, Jewell-Motz EA, et al. Tissue- and isoform-specific kinetic behavior of the Na,K-ATPase. J Biol Chem 1994;269:16668-16676
25. Sahin-Erdemli I, Medford RM, Songu-Mize E. Regulation of Na+,K(+)-ATPase α-subunit isoforms in rat tissues during hypertension. Eur J Pharmacol 1995;292:163-171
26. Riedl U, Barocka A, Kolem H, et al. Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder: a study with magnetic resonance spectroscopy. Biol Psychiatry 1997;41:844-850
27. Kabakov AY, Karkanias NB, Lenox RH, et al. Synapse specific accumulation of lithium in intracellular microdomains: a model for uncoupling coincidence detection in the brain. Synapse. In press
28. Goodnick PJ, Gershon ES. Lithium. In: Lajtha A, ed. Handbook of Neurochemistry. New York, NY: Plenum Press 1985:103-149
29. Bunney WE, Garland-Bunney BL. Mechanism of action of lithium in affective illness: basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:553-565
30. Bunney WE Jr. Neuronal receptor function in psychiatry: strategy and theory. In: Usdin E, Bunney WE Jr, Davis JM, eds. Neuroreceptors: Basic and Clinical Aspects. New York, NY: John Wiley & Sons; 1981:241-255
31. Gallager DW, Pert A, Bunney WE Jr. Haloperidol-induced presynaptic dopamine supersensitivity is blocked by chronic lithium. Nature 1978;273: 309-312
32. 3H-spiroperidol binding in rat striatum. Eur J Pharmacol 1980;67:321-322
33. Verimer T, Goodale DB, Long JP, et al. Lithium effects on haloperidol-induced pre- and postsynaptic dopamine receptor supersensitivity. J Pharm Pharmacol 1980;32:665-666
34. Bloom FE, Baetge G, Deyo S, et al. Chemical and physiological aspects of the actions of lithium and antidepressant drugs. Neuropharmacology 1983; 22:359-365
35. Klawans HL, Weiner WJ, Nausieda PA. The effect of lithium on an animal model of tardive dyskinesia. Prog Neuropsychopharmacol 1976;1:53-60
36. Staunton DA, Magistretti PJ, Shoemaker WJ, et al. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum, I: locomotor activity and behavioral supersensitivity. Brain Res 1982;232:391-400
37. Staunton DA, Magistretti PJ, Shoemaker WJ, et al. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum, II: no effect on denervation or neuroleptic-induced supersensitivity. Brain Res 1982; 232:401-412
38. Allikmets LH, Stanley M, Gershon S. The effect of lithium on chronic haloperidol enhanced apomorphine aggression in rats. Life Sci 1979;25: 165-170
39. Huey LY, Janowshy DS, Judd LL, et al. Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes. Psychopharmacology (Berl) 1981;73:161-164
40. Pert A, Rosenblatt JE, Sivit C, et al. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978;201:171-173
41. van Kammen DP, Docherty JP, Marder SR, et al. Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia. Psychopharmacology (Berl) 1985;87:111-115
42. Friedman E, Wang H-Y. Effect of chronic lithium treatment on 5-hyroxytryptamine autoreceptors and release of 5-[3H]hydroxytryptamine from rat brain cortical, hippocampal, and hypothalamic slices. J Neurochem 1988;50:195-201
43. 2 adrenoceptor mediated function in mice. Psychopharmacology (Berl) 1986;90:482-487
44. Hotta I, Yamawaki S. Possible involvement of presynaptic 5-HT autoreceptors in effect of lithium on 5-HT release in hippocampus of rat. Neuropharmacology 1988;27:987-992
45. Mork A, Geisler A. Effects of GTP on hormone-stimulated adenylate cyclase activity in cerebral cortex, striatum, and hippocampus from rats treated chronically with lithium. Biol Psychiatry 1989;26:279-288
46. Newman ME, Drummer D, Lerer B. Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J Pharmacol Exp Ther 1990;252:826-831
47. Wang HY, Friedman E. Chronic lithium: desensitization of autoreceptors mediating serotonin release. Psychopharmacology (Berl) 1988;94:312-314
48. Blier P, de Montigny C. Short-term lithium administration enhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS. Psychopharmacology (Berl) 1985;113:69-77
49. 1A receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse 1987;1:225-232
50. Dilsaver SC, Coffman JA. Cholinergic hypothesis of depression: a reappraisal. J Clin Psychopharmacol 1989;9:173-179
51. Kofman O, Belmaker RH, Grisaru N, et al. Myo-inositol attenuates two specific behavioral effects of acute lithium in rats. Psychopharmacol Bull 1991;27:185-190
52. Tricklebank MD, Singh L, Jackson A, et al. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res 1991;558:145-148
53. Evans MS, Zorumski CF, Clifford DB. Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience 1990;38:457-468
54. Emerich HM, Zerssen DV, Kissling W, et al. Effect of sodium valproate on mania. Archives of Psychiatry 1980;229:1-16
55. Lloyd KG, Morselli PL, Bartholini G. GABA and affective disorders. Medical Biology 1987;65:159-165
56. Squires RF, Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of functional psychosis. Neurochem Res 1991;16:1099-1111
57. Berrettini WH, Nurnberger JI Jr, Hare T, et al. Plasma and CSF GABA in affective illness. Br J Psychiatry 1982;141:483-487
58. Petty F, Kramer GL, Rush AJ. Low plasma γ-aminobutyric acid levels in male patients with depression. Biol Psychiatry 1992;32:354-363
59. Post RM, Ballenger JC, Hare TA, et al. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res Bull 1980;5(suppl 2):755-759
60. Petty F, Kramer GL, Fulton M, et al. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 1993;9:125-132
61. Berrettini WH, Nurnberger JI Jr, Hare T, et al. Reduced plasma and CSF γ-aminobutyric acid in affective illness: effect of lithium carbonate. Biol Psychiatry 1983;18:185-194
62. Berrettini WH, Nurnberger JI Jr, Hare T, et al. CSF GABA in euthymic manic-depressive patients and controls. Biol Psychiatry 1986;21:842-844
63. Petty F, Rush AJ, Davis JM, et al. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 1996;39:278-284
64. Ahluwalia P, Singhal RL. Monoamine uptake into synaptosomes from various regions of rat brain following lithium administration and withdrawal. Neuropharmacology 1981;20:483-487
65. Gottesfeld Z, Ebstein BS, Samuel D. Effect of lithium on concentrations of glutamate and GABA levels in amygdala and hypothalamus of rat. Nature 1971;234:124-125
66. Maggi A, Enna SJ. Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment. J Neurochem 1980;34:888-892
67. Bernasconi R. The GABA hypothesis of affective illness: influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Adenhoff JB, Lux HM, eds. Basic Mechanisms in the Action of Lithium. Amsterdam, The Netherlands: Excerpta Medica; 1982:183-192
68. 3H]-γ-aminobutyric acid from striatal neurons in primary culture potentiated by lithium ions. Mol Pharmacol 1990;38:229-236
69. Dixon JF, Los GV, Hokin LE. Lithium stimulates glutamate "release" and inositol 1,4,5-triphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc Natl Acad Sci U S A 1994;91:8358-8362
70. Ormandy GC, Jope RS, Snead OC. Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats. Exp Neurol 1989;106:172-180
71. 1 neurons during chronic lithium treatment. Hippocampus 1992;2:279-286
72. Sivam SP, Krause JE, Takeuchi K, et al. Lithium increases rat striatal β- and gamma-preprotachykinin messenger RNAs. J Pharmacol Exp Ther 1989; 248:1297-1301
73. Sivam SP, Takeuchi K, Li S, et al. Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. Brain Res 1988; 427:155-163
74. Blancquaert JP, Lefebvre RA, Willems JL. Antiaversive properties of opioids in the conditioned taste aversion test in the rat. Pharmacol Biochem Behav 1987;27:437-441
75. Lieblich I, Yirmiya R. Naltrexone reverses a long term depressive effect of atoxic lithium injection on saccharin preference. Physiol Behav 1987;39: 547-550
76. Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) 1985;86:274-280
77. Shippenberg TS, Herz A. Influence of chronic lithium treatment upon the motivational effects of opioids: alteration in the effects of mu-but not kappa-opioid receptor ligands. J Pharmacol Exp Ther 1991;256:1101-1106
78. Shippenberg TS, Millan MJ, Mucha RF, et al. Involvement of β-endorphin and mu-opioid receptors in mediating the aversive effect of lithium in the rat. Eur J Pharmacol 1988;154:135-144
79. Berrettini WH, Nurnberger JI, Scheinin M, et al. Cerebrospinal fluid and plasma monamines and their metabolites in euthymic bipolar patients. Biol Psychiatry 1985;20:257-269
80. Berrettini WH, Nurnberger JI Jr, Zerbe RL, et al. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987;150:208-212
81. Allison JH, Stewart MA. Reduced brain inositol in lithium treated rats. Nature: New Biology 1971;233:267-268
82. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. J Biol Chem 1980;255:10896-10901
83. Batty IH, Downes CP. The inhibition of phosphoinositide synthesis and muscarinic-receptor-mediated phospholipase C activity by Li+ as secondary, selective consequences of inositol depletion in 1321N1 cells. Biochem J 1994;297:529-537
84. Sherman WR. Lithium and the phosphoinositide signalling system. In: Birch NJ, ed. Lithium and the Cell. London, England: Academic Press; 1991:121-157
85. +. J Neurochem 1995;65:2279-2289
86. Nahorski SR, Ragan CI, Challiss RAJ. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol Sci 1991;12:297-303
87. Nahorski SR, Jenkinson S, Challiss RA. Disruption of phosphoinositide signalling by lithium. Biochem Soc Trans 1992;20:430-434
88. Berridgc MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-419
89. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206:587-595
90. Kennedy ED, Challiss RAJ, Ragan CI, et al. Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochem J 1990;267:781-786
91. Varney MA, Godfrey PP, Drummond AH, et al. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH, pituitary cells. Mol Pharmacol 1992;4:671-678
92. Maslanski JA, Leshko L, Busa WB. Lithium-sensitive production of inositol phosphates during amphibian embryonic mesoderm induction. Science 1992;256:243-245
93. Moore GJ, Bebchuk JM, Manji HK. Proton MRS in manic depressive illness: monitoring of lithium induced modulation of brain myo-inositol. Society of Neuroscience 1997;23:335-336
94. Manji HK, Lenox RH. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994;16:11-28
95. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996;67:767-777
96. Manji HK, Chen G, Hsiao JK, et al. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996;57(suppl 13):34-46
97. Becchetti A, Whitaker M. Lithium blocks cell cycle transitions in the first cell cycles of sea urchin embryos, an effect rescued by myo-inositol. Development 1997;124:1099-1107
98. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994;47:429-441
99. Anderson PH, Geisler A. Lithium inhibition of forskolin-stimulated adenylate cyclase. Neuropsychobiology 1984;12:1-3
100. Ebstein RP, Hermoni M, Belmaker RH. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J Pharmacol Exp Ther 1980;213:161-167
101. Fom J, Valdecasas FG. Effects of lithium on brain adenyl cyclase activity. Biochem Pharmacol 1971;20:2773-2779
102. Geisler A, Klysner R, Andersen PH. Influence of lithium in vitro and in vivo on the catecholamine-sensitive cerebral adenylate cyclase systems. Acta Pharmacologica et Toxicologica (Copenh) 1985;56:80-97
103. Mork A, Geisler A. Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol 1987;60:241-248
104. Mork A, Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neuropharmacology 1989;28:307-311
105. Mork A, Geisler A. Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain. Eur J Pharmacol 1989;168:347-354
106. Mork A, Geisler A. Effects of lithium treatment on agonist-enhanced extracellular concentrations of cyclic AMP in the dorsal hippocampus of freely moving rats. J Neurochem 1995;65:134-139
107. Newman ME, Belmaker RH. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987;26:211-217
108. Dousa TP. Interaction of lithium with vasopressin-sensitive cyclic AMP system of human renal medulla. Endocrinology 1974;95:1359-1366
109. Goldberg H, Clayman P, Skorecki K. Mechanism of Li inhibition on vasopressin-sensitive adenylate cyclase in cultured renal epithelial cells. Am J Physiol 1988;24:F995-F1002
110. Tseng FY, Pasquali D, Field JB. Effects of lithium on stimulated metabolic parameters in dog thyroid slices. Acta Endocrinology (Copenhagen) 1989;121:615-620
111. Urabe M, Hershman JM, Pang XP, et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991;129:807-814
112. Newman M, Klein E, Birmaher B, et al. Lithium at therapeutic concentrations inhibits human brain noradrenaline sensitive cyclic AMP accumulation. Brain Res 1983;278:380-381
113. Masana MI, Bitran JA, Hsiao JK, et al. Lithium effects on noradrenergic linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. Brain Res 1991;538:333-336
114. Godfrey PP, McClue SJ, White AM, et al. Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J Neurochem 1989;52:498-506
115. Song L, Jope R. Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions. J Neurochem 1992;58: 2200-2206
116. Avissar S, Schreiber G, Danon A, et al. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988;331: 440-442
117. Ellis J, Lenox RH. Receptor coupling to G proteins: interactions not affected by lithium. Lithium 1991;2:141-147
118. Manji HK, Chen G, Shimon H, et al. Guanine nucleotide-binding proteins in bipolar affective disorder: effects of long-term lithium treatment. Arch Gen Psychiatry 1995;52:135-144
119. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992; 149:746-760
120. i modulation of adenylate cyclase in brain. J Neurochem 1992; 59:200-205
121. Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Presented at the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
122. Greenwood AF, Jope RS. Brain G-protein proteolysis by calpain: enhancement by lithium. Brain Res 1994;636:320-326
123. i2, α- sub-unit mRNA levels in rat cortex. Eur J Pharmacol 1991;206:165-166
124. Hsiao JK, Colison J, Bartko JJ, et al. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1993;50:606-614
125. i-protein α subunit in rat cerebral cortex. Proc Natl Acad Sci U S A 1991;88:10634-10637
126. Thiele EA, Eipper BA. Effect of secretagogues on components of the secretory system in AtT-20 cells. Endocrinology 1990;126:809-817
127. Young LT, Woods CM. Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. Eur J Pharmacol 1996; 309:215-218
128. Nestler EJ, Terwilliger RZ, Duman RS. Regulation of endogenous ADP-ribosylation by acute and chronic lithium in rat brain. J Neurochem 1995; 64:2319-2324
129. Huang KP. The mechanism of protein kinase C activation. Trends Neurosci 1989;12:425-432
130. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-614
131. Stabel S, Parker PJ. Protein kinase C. Pharmacol Ther 1991;51:71-95
132. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 1994;17:551-567
133. Manji HK, Etcheberrigaray R, Chen G, et al. Lithium dramatically decreases membrane-associated PKC in the hippocampus: selectivity for the a isozyme. J Neurochem 1993;61:3203-3210
134. Manji HK, Bersudsky U, Chen G, et al. Modulation of PKC isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 1996;15:370-381
135. Leli U, Hauser G. Lithium modifies diacylglycerol levels and protein kinase C in neuroblastoma cells. In: Abstracts of the 8th International Conference on Second messengers and phosphoproteins: August 3-6, 1992; Glasgow, Scotland
136. Li X, Jope RS. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC 12 cells. J Neurochem 1995;65:2500-2508
137. Chen G, Manji HK, Hawver DB, et al. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem 1994;63: 2361-2364
138. Huang FL, Yoshida Y, Cunha-Melo JR, et al. Differential down-regulation of protein kinase C isozymes. J Biol Chem 1989;264:4238-4243
139. Isakov N, McMahon P, Altman A. Selective post-transcriptional down-regulation of protein kinase C isozymes in Leukemic T cells chronically treated with phorbol ester. J Biol Chem 1990;265:2091-2097
140. Oda T, Shearman MS, Nishizuka Y. Synaptosomal protein kinase C subspecies, B: down-regulation promoted by phorbol ester and its effect on evoked norepinephrine release. J Neurochem 1991;56:1263-1269
141. Watson DG, Wainer BH, Lenox RH. Phorbol ester- and retinoic acid-induced regulation of the protein kinase C substrate MARCKS in immortalized hippocampal cells. J Neurochem 1994;63:1666-1674
142. Lenox RH, Watson DG, Patel J, et al. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570: 333-340
143. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992;71:713-716
144. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993;268:1501-1504
145. Lenox RH, McNamara RK, Watterson JM, et al. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996;57(suppl 13):23-31
146. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of PKC-mediated mood stabilizers. J Pharmacol Exp Ther. In press
147. Bohmann D. Transcription factor phosphorylation: a link between signal transduction and the regulation of gene expression. Cancer Cells 1990;2: 337-343
148. Hunter T, Karin M. The regulation of transcription by phoshphorylation. Cell 1992;70:377-387
149. Divish MM, Sheftel G, Boyle A, et al. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. J Neurosci Res 1991;28:40-48
150. Gao XM, Fukamauchi F, Chuang DM. Long-term biphasic effects of lithium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochem Int 1993;22: 395-403
151. Kalasapudi VD, Sheftel G, Divish MM, et al. Lithium augments fos protooncogene expression in PC 12 pheochromocytoma cells: implications for therapeutic action of lithium. Brain Res 1990;521:47-54
152. Miller JC, Mathe AA. Basal and stimulated c-fos mRNA expression in the rat brain: effect of chronic dietary lithium. Neuropsychopharmacology 1997;16:408-418
153. Kislauskis E, Dobner PR. Mutually dependent response elements in the cis-regulatory region of the neurotensin/neuromedin N gene integrate environmental stimuli in PC12 cells. Neuron 1990;4:783-795
154. Pfeiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991;16:505-515
155. Weiner ED, Kalaaspudi VD, Papolos DF, et al. Lithium augments pilocarpine-induced fos gene expression in brain. Brain Res 1991;553: 117-122
156. Zachrisson O, Mathe AA, Stenfors C, et al. Regional-specific effects of chronic lithium on administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. Neurosci Lett 1995;194:89-92
157. Chen G, Yuan P, Wawyer DB, et al. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997; 16:238-245
158. Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997;17:12-17
159. Bond PA, Brooks BA, Judd A. The distribution of lithium, sodium and magnesium in rat brain and plasma after various periods of administration of lithium in the diet. Br J Pharmacol 1975;53:235-239
160. Ebadi MS, Simmons VJ, Hendrickson MJ, et al. Pharmakokinetics of lithium and its regional distribution in rat brain. Eur J Pharmacol 1974; 27:324-329
161. Edelfors S. Distribution of sodium, potassium and lithium in the brain of lithium-treated rats. Acta Pharmacologica et Toxicologica 1975;37: 387-392
162. Heurteaux C, Baumann N, Lachapelle F, et al. Lithium distribution in the brain of normal mice and of "quacking" dysmyelinating mutants. J Neurochem 1986;46:1317-1321
163. Mukherjee BP, Bailey PT, Pradhan SN. Temporal and regional differences in brain concentrations of lithium in rats. Psychopharmacology (Berl) 1976;48:119-121
164. Nelson SC, Herman MM, Bensch KG, et al. Localization and quantitation of lithium in rat tissue following intraperitoneal injections of lithium chloride. II: Brain. J Pharm Exp Ther 1980;212:11-15
165. 7Li NMR imaging and localized spectroscopy of rat brain. Magnetic Resonance Medicine 1992;25:308-318
166. Sandner G, Di Scala G, Oberling P, et al. Distribution of lithium in the rat brain after a single administration known to elicit aversive effects. Neurosci Lett 1994;166:1-4
167. Savalainen KM, Hirvonen MR, Tarhanen J, et al. Changes in cerebral inositol-1-phosphate concentrations in LiCl-treated rats: regional and strain differences. Neurochem Res 1990;15:541-545
168. Smith DF, Amdisen A. Lithium distribution in rat brain after long-term central administration by minipump. J Pharm Phamacol 1981;33: 805-806
169. Spirtes MA. Lithium levels in monkey and human brain after chronic, therapeutic, oral dosage. Pharmacol Biochem Behav 1976;5:143-147
170. Thellier M, Wissocq JC, Heurteaux C. Quantitative microlocation of lithium in the brain by a (n,α) nuclear reaction. Nature 1980;283:299-302
171. Allison JH, Boshans RL, Hallcher LM, et al. The effects of lithium on myo-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum of the rat. J Neurochem 1980;34:456-458
172. 1-adrenergic receptors and stimulation of [3H]inositol metabolism in rat brain: regional distribution and parallel inactivation. Brain Res 1985;341:7-15
173. Jope RS, Song L, Li PP, et al. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 1996; 66:2402-2409
174. Rooney TA, Nahorski SR. Regional characterization of agonist and depolarization-induced phosphoinositide hydrolysis in rat brain. J Pharmacol Exp Ther 1986;239:873-880
175. Sherman WR, Gish BG, Honchar MP, et al. Effects of lithium on phosphoinositide metabolism in vivo. Federation Proceedings 1986;45: 2639-2646
176. Gani D, Downes CP, Bramham J. Lithium and myo-inositol homeostasis. Biochim Biophys Acta 1993;1177:253-269
177. Heacock AM, Seguin EB, Agranoff BW. Measurement of receptor-activated phosphoinositide turnover in rat brain: nonequivalence of inositol phosphate and CDP-diacylglycerol formation. J Neurosci 1993;60: 1087-1092
178. Sarri E, Picatoste F, Claro E. Neurotransmitter specific profiles of inositol phosphates in rat brain cortex: relation to the mode of receptor activation of phosphoinositide phospholipase C. J Pharmacol Exp Ther 1995;272: 77-84